Search

Your search keyword '"Lillicrap, Mark"' showing total 29 results
Start Over Author "Lillicrap, Mark"
29 results on '"Lillicrap, Mark"'

4. Hinchingbrooke Hospital’s reply to “inadequate” rating on patient care

Author

Hamilton, Suzanne, Ranjan, Shashank, Bourne, Rupert, Alvi, Atif, Wojcik, Andrew, Bashford, Sally, Harris, Adrian, Martin, Alexander, Wazait, Hassan, Hasan, Rizwan, Rene, Cornelius, Chang, Lydia, Mitchell, David, Johnson, Helen, Hille, Ingo, Barabas, Tony, Pradhan, Ashish, Jenabzadeh, Reza, Mohamed, Ahmed, Jamali, Nobila, Boland, Colin, Matthews, Annelise, Pathak, Sangeeta, Akerele, Toks, Morgan, Tony, Di Franco, Filippo, Ward, David, Srouji, Ibrahim, Hubbard, Catherine, Hoggarth, Catherine, Palmer, Cheryl, Schumacher, Hagen, Shiew, Marianne, Meldou, Mathews, Anitha, Felli, Bhanti, Dubash, Sayam, Manzo, Erika, Connick, Rona, Taveres, Jose, Walsh, Kevin, and Lillicrap, Mark

Published
2015

10. A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis

Author

Kitas, George D, Nightingale, Peter, Armitage, Jane, Sattar, Naveed, Belch, Jill JF, Symmons, Deborah PM, Williams, Hawys, Vasishta, Shobna, Storey, Rebecca, Bruce, Ian, Durrington, Paul, McInnes, Iain, Situnayake, Deva, Struthers, Allan, Lowe, Gordon, Fox, Keith, Haskard, Dorian, Dore, Caroline, Bosworth, Ailsa, Frenneaux, Michael, Edwards, Christopher, Emberson, Jonathan, Bax, Deborah, Cobbe, Stuart, Stott, David, Sturrock, Roger, Macfarlane, Peter, Klocke, Rainer, Pullar, Tom, Tan, Su, Knight, Susan, Rowe, Iain, Kumar, Pradeep, Goodson, Nicky, Mulherin, Diarmuid, Brzeski, Micheal, Gardiner, Philip, Walker, David, Callaghan, Rob, Allen, Margaret, McCarey, David, George, Emmanuel, Deighton, Chris, Kirkham, Bruce, Teh, Lee-Suan, Luqmani, Raashid, Chakravarty, Kuntal, Roussou, Euthalia, Nixon, Jenny, Richards, Selwyn, Scott, David, Woolf, Tony, Prouse, Peter, Packham, Jonathan, Davies, Martin, DeLord, Denise, O'Neill, Terence, Pande, Ira, Watts, Richard, Rankin, Elizabeth, Papasawas, George, Emery, Paul, Morgan, Ann, Sinha, Arvind, Dasgupta, Bhaskar, Creamer, Paul, Zoma, Asad, Walsh, David, Van-Laar, Jaap, Capps, Nigel, Cairns, Andrew, Marguerie, Christopher, Kumar, Namita, Abernethy, Rikki, Lillicrap, Mark, Ralston, Stuart, Makadsi, Raad, Hopkinson, Neil, Akil, Mohammed, Ahmad, Yasmeen, Adler, Matthew, Bukhari, Marwan, Sanders, Paul, Binymin, Khalid, Hassan, Alaa, Hughes, Rod, Irani, Mike, O'Reilly, David, Sainsbury, Paul, Richmond, Ruth, Malgorzata, Magliano, Nisar, Mohammed, McEntergart, Ann, Roy, Dipak, Marks, Jeffrey, Batley, Michael, Mahmud, Taher, McKenna, Frank, Harris, Helen, Smyth, Anita, Tunn, Eddie, Young, Adam, Baburaj, Krishnan, Thomas, Joegi, Hall, Frances, Marshall, Tarnya, Rao, Chandini, Dixey, Josh, Gendi, Nagui, Birrell, Fraser, Chelliah, Gladstone, Fishman, Daniel, Knights, Sally, Coady, David, Smith, Bill, Harrison, Beverley, Naz, Sophia, Siebert, Stefan, Chan, Anthony, Putchakayala, Kiran, Al-Ansari, Atheer, Gough, Andrew, Pyne, Dev, Patel, Yusaf, Isdale, Amanda, Harvie, John, Consortium, TRACERA, Comm, Trial Management, Comm, Trial Steering, Comm, Data Monitoring, Comm, Endpoints, and Principal, TRACERA Recruiting Ctr

Published
2019

11. A multicenter, randomized, placebo‐controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis

Author

Kitas, George D., Nightingale, Peter, Armitage, Jane, Sattar, Naveed, Belch, Jill J. F., Symmons, Deborah P. M., Kitas, George, Belch, Jill, Symmons, Deborah, Williams, Hawys, Vasishta, Shobna, Storey, Rebecca, Bruce, Ian, Durrington, Paul, McInnes, Iain, Situnayake, Deva, Struthers, Allan, Lowe, Gordon, Fox, Keith, Haskard, Dorian, Dore, Caroline, Bosworth, Ailsa, Frenneaux, Michael, Edwards, Christopher, Emberson, Jonathan, Bax, Deborah, Cobbe, Stuart, Stott, David, Sturrock, Roger, Macfarlane, Peter, Klocke, Rainer, Pullar, Tom, Knight, Susan, Rowe, Iain, Kumar, Pradeep, Goodson, Nicky, Mulherin, Diarmuid, Brzeski, Micheal, Gardiner, Philip, Walker, David, Callaghan, Rob, Allen, Margaret, McCarey, David, George, Emmanuel, Deighton, Chris, Kirkham, Bruce, Teh, Lee‐Suan, Luqmani, Raashid, Chakravarty, Kuntal, Nixon, Jenny, Richards, Selwyn, Scott, David, Woolf, Tony, Prouse, Peter, Packham, Jonathan, Davies, Martin, DeLord, Denise, O’Neill, Terence, Pande, Ira, Harvie, John, Watts, Richard, Rankin, Elizabeth, Papasavvas, George, Emery, Paul, Sinha, Arvind, Dasgupta, Bhaskar, Creamer, Paul, Zoma, Asad, Walsh, David, Van‐Laar, Jaap, Capps, Nigel, Cairns, Andrew, Marguerie, Christopher, Kumar, Namita, Abernethy, Rikki, Lillicrap, Mark, Ralston, Stuart, Makadsi, Raad, Hopkinson, Neil, Tan, Su, Akil, Mohammed, Ahmad, Yasmeen, Adler, Matthew, Bukhari, Marwan, Sanders, Paul, Roussou, Euthalia, Binymin, Khalid, Hassan, Alaa, Hughes, Rod, O’Reilly, David, Sainsbury, Paul, Richmond, Ruth, Malgorzata, Magliano, Nisar, Mohammed, McEntergart, Ann, Roy, Dipak, Marks, Jeffrey, Batley, Michael, McKenna, Frank, Irani, Mike, Harris, Helen, Smyth, Anita, Tunn, Eddie, Young, Adam, Thomas, Joegi, Hall, Frances, Marshall, Tarnya, Rao, Chandini, Baburaj, Krishnan, Dixey, Josh, Gendi, Nagui, Birrell, Fraser, Chelliah, Gladstone, Morgan, Ann, Fishman, Daniel, Knights, Sally, Coady, David, Smith, Bill, Harrison, Beverley, Siebert, Stefan, Chan, Anthony, Putchakayala, Kiran, Al‐Ansari, Atheer, Gough, Andrew, Naz, Sophia, Pyne, Dev, Mahmud, Taher, Patel, Yusaf, and Isdale, Amanda

Abstract

Objective:\ud \ud Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVEs in RA patients.\ud Methods:\ud \ud A randomized, double‐blind, placebo‐controlled trial was designed to detect a 32% CVE risk reduction based on an estimated 1.6% per annum event rate with 80% power at P < 0.05. RA patients age >50 years or with a disease duration of >10 years who did not have clinical atherosclerosis, diabetes, or myopathy received atorvastatin 40 mg daily or matching placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, transient ischemic attack, or any arterial revascularization. Secondary and tertiary end points included plasma lipids and safety.\ud Results:\ud \ud A total of 3,002 patients (mean age 61 years; 74% female) were followed up for a median of 2.51 years (interquartile range [IQR] 1.90, 3.49 years) (7,827 patient‐years). The study was terminated early due to a lower than expected event rate (0.70% per annum). Of the 1,504 patients receiving atorvastatin, 24 (1.6%) experienced a primary end point, compared with 36 (2.4%) of the 1,498 receiving placebo (hazard ratio [HR] 0.66 [95% confidence interval (95% CI) 0.39, 1.11]; P = 0.115 and adjusted HR 0.60 [95% CI 0.32, 1.15]; P = 0.127). At trial end, patients receiving atorvastatin had a mean ± SD low‐density lipoprotein (LDL) cholesterol level 0.77 ± 0.04 mmoles/liter lower than those receiving placebo (P < 0.0001). C‐reactive protein level was also significantly lower in the atorvastatin group than the placebo group (median 2.59 mg/liter [IQR 0.94, 6.08] versus 3.60 mg/liter [IQR 1.47, 7.49]; P < 0.0001). CVE risk reduction per mmole/liter reduction in LDL cholesterol was 42% (95% CI −14%, 70%). The rates of adverse events in the atorvastatin group (n = 298 [19.8%]) and placebo group (n = 292 [19.5%]) were similar.\ud Conclusion:\ud \ud Atorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists’ Collaboration meta‐analysis of statin effects in other populations.

Published
2019

14. Consensus statement on the content of clinical reasoning curricula in undergraduate medical education.

Author

Cooper, Nicola, Bartlett, Maggie, Gay, Simon, Hammond, Anna, Lillicrap, Mark, Matthan, Joanna, and Singh, Mini

Subjects
CONSENSUS (Social sciences), DECISION making, CURRICULUM, MEDICAL education, MEDICAL history taking, MEDICAL logic, PHYSICAL diagnosis, PROBLEM solving, DISEASE management, TEACHING methods, ROUTINE diagnostic tests
Abstract

Effective clinical reasoning is required for safe patient care. Students and postgraduate trainees largely learn the knowledge, skills and behaviours required for effective clinical reasoning implicitly, through experience and apprenticeship. There is a growing consensus that medical schools should teach clinical reasoning in a way that is explicitly integrated into courses throughout each year, adopting a systematic approach consistent with current evidence. However, the clinical reasoning literature is 'fragmented' and can be difficult for medical educators to access. The purpose of this paper is to provide practical recommendations that will be of use to all medical schools. Members of the UK Clinical Reasoning in Medical Education group (CReME) met to discuss what clinical reasoning-specific teaching should be delivered by medical schools (what to teach). A literature review was conducted to identify what teaching strategies are successful in improving clinical reasoning ability among medical students (how to teach). A consensus statement was then produced based on the agreed ideas and the literature review, discussed by members of the consensus statement group, then edited and agreed by the authors. The group identified 30 consensus ideas that were grouped into five domains: (1) clinical reasoning concepts, (2) history and physical examination, (3) choosing and interpreting diagnostic tests, (4) problem identification and management, and (5) shared decision making. The literature review demonstrated a lack of effectiveness for teaching the general thinking processes involved in clinical reasoning, whereas specific teaching strategies aimed at building knowledge and understanding led to improvements. These strategies are synthesised and described. What is taught, how it is taught, and when it is taught can facilitate clinical reasoning development more effectively through purposeful curriculum design and medical schools should consider implementing a formal clinical reasoning curriculum that is horizontally and vertically integrated throughout the programme. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. Arthritis associated with enteric infection.

Author

Hill Gaston, Hill Gaston, J S, and Lillicrap, Mark S

Abstract

Reactive arthritis is classically seen following infection with enteric pathogens such as Yersinia, Salmonella, Campylobacter and Shigella. Inflammatory arthritis has also been described following other enteric infection with organisms such as Clostridium difficile, Brucella and Giardia. Furthermore, arthritis is seen in Whipple's disease, caused by the actinomycete Tropheryma whippelii. This chapter reviews the current understanding of these conditions (with the exception of Brucella, which is discussed in a subsequent chapter). The epidemiology is reviewed, and the contribution of both host and organism to the aetiology and pathogenesis is discussed with particular discussion of the role of HLA-B27 in host susceptibility. Recent work exploring evidence for traffic of pathogenic organisms to the joint is highlighted. A practical approach to the diagnosis and management of the condition is then formulated based, where possible, on clinical trial evidence. [ABSTRACT FROM AUTHOR]

Published
2003

24. All doctors can benefit from reflective practice forums.

Author

Morris, Rachel and Lillicrap, Mark

Subjects
*COMMUNICATION, *HOSPITAL medical staff, *PHYSICIANS, *REFLECTION (Philosophy), *ROLE models
Abstract

A letter to the editor is presented commenting on a letter that appeared in the February 13, 2016 issue which focuses on the benefits that doctors in Great Britain can derive from reflective practice forums.

Published
2016

27. List of Contributors

Author

Amft, E. Nicole, Beggs, Ian, Brown, Matthew A., Bruce, Ian N., Buckley, Christopher D., Clarke, Anthony K., Edmonds, Sally E., Eunson, Paul, Gaston, Hill, Hennell, Sheena, Hooper, Geoff, Joseph, Benjamin, Keating, John F., Kingsley, Gabrielle H., Lillicrap, Mark, Luqmani, Raashid, Macnicol, Malcolm F., Marshall, Robert W., Mok, Jacqueline Y.Q., Newton, Julia L., Nuki, George, Paterson, Mark, Porter, Daniel, Ralston, Stuart H., Robb, James, Scott, David L., Sherlock, David A., Stableford, Zoe, Tsirikos, Athanasios I., and Wilkinson, Nick

Full Text
View/download PDF

28. Should medical schools relax academic admission criteria?

Author

Tarmey D, Wood DF, Lillicrap MS, and Canuto HC

Subjects
Achievement, United Kingdom, School Admission Criteria, Schools, Medical
Abstract

Competing Interests: Competing interests: All authors have read and understood BMJ policy on declaration of interests and have no relevant interests to declare.

Published
2019
Full Text
View/download PDF

29. Hinchingbrooke Hospital's reply to "inadequate" rating on patient care.

Author

Hamilton S, Ranjan S, Bourne R, Alvi A, Wojcik A, Bashford S, Harris A, Martin A, Wazait H, Hasan R, Rene C, Chang L, Mitchell D, Johnson H, Hille I, Barabas T, Pradhan A, Jenabzadeh R, Mohamed A, Jamali N, Boland C, Matthews A, Pathak S, Akerele T, Morgan T, Di Franco F, Ward D, Srouji I, Hubbard C, Hoggarth C, Palmer C, Schumacher H, Shiew M, Meldou, Mathews A, Felli B, Dubash S, Manzo E, Connick R, Taveres J, Walsh K, and Lillicrap M

Subjects
England, Humans, Public-Private Sector Partnerships, Hospitals, General, Patient Care standards, Quality of Health Care standards
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results